[18F]2-Fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil

British Journal of Cancer

Volumn 97, Issue 7, 2007, Pages 902-909

  Suttie, S A ^a   Park, K G M ^a   Smith, T A D ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Apoptosis; FDG PET; Gastric; Glucose transport; Hexokinase

Indexed keywords

CISPLATIN; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; HEXOKINASE; LIPOCORTIN 5; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CONTROLLED STUDY; ENZYME ACTIVITY; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; LETHAL DOSE; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; ADENOCARCINOMA; CELL CULTURE; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; FLOW CYTOMETRY; METABOLISM; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; STOMACH TUMOR;

ADENOCARCINOMA; ANNEXIN A5; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; CELL SURVIVAL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; FLOW CYTOMETRY; FLUORODEOXYGLUCOSE F18; FLUOROURACIL; HUMANS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 34948906246     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603971     Document Type: Article

References (61)

1. Al-Saeedi F, Welch AE, Smith TA (2005) [methyl-(3)H]Choline incorporation into MCF7 tumour cells: correlation with proliferation. Eur J Nucl Med Mol Imaging 32: 660-667
2. Aloj L, Caraco C, Jagoda E, Eckelman WC, Neumann RD (1999) Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Res 59: 4709-4714
3. Barros LF, Porras OH, Bittner CX (2005) Why glucose transport in the brain matters for PET. Trends Neurosci 28: 117-119
4. Barry MA, Behnke CA, Eastman A (1990) Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 40: 2353-2362
5. Bartkowiak D, Hemmer J, Rottinger E (1992) Dose dependence of the cytokinetic and cytotoxic effects of epirubicin in vitro. Cancer Chemother Pharmacol 30: 189-192
6. Basu S, Alavi A (2007) Defining co-related parameters between 'metabolic' flare and 'clinical', 'biochemical', and 'osteoblastic' flare and establishing guidelines for assessing response to treatment in cancer. Eur J Nucl Med Mol Imaging 34: 441-443
7. Brown RS, Leung JY, Kison PV, Zasadny KR, Flint A, Wahl RL (1999) Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med 40: 556-565
8. Burgman P, Odonoghue JA, Humm JL, Ling CC (2001) Hypoxia-Induced increase in FDG uptake in MCF7 cells. J Nucl Med 42: 170-175
9. Burrows RC, Freeman SD, Charlop AW, Wiseman RW, Adamsen TC, Krohn KA, Spence AM (2004) [18F]-2-fluoro-2-deoxyglucose transport kinetics as a function of extracellular glucose concentration in malignant glioma, fibroblast and macrophage cells in vitro. Nucl Med Biol 31: 1-9
10. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-942
11. Cersosimo RJ, Hong WK (1986) Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol 4: 425-439
12. Chow KC, Ross WE (1987) Topoisomerase-specific drug sensitivity in relation to cell cycle progression. Mol Cell Biol 7: 3119-3123
13. Cloherty EK, Levine KB, Graybill C, Carruthers A (2002) Cooperative nucleotide binding to the human erythrocyte sugar transporter. Biochemistry 41: 12639-12651
14. Couper G, Park K (2003) In vitro response to chemotherapy: evidence of resistance to neo-adjuvant chemotherapy in upper gastrointestinal cancer. Br J Surg 90: 50
15. Couper GW, McAteer D, Wallis F, Norton M, Welch A, Nicolson M, Park KG (1998) Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer. Br J Surg 85: 1403-1406
16. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, Participants MT (2006) Perioperative chemotherapy vs surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11-20
17. Dittmann H, Dohmen BM, Kehlbach R, Bartusek G, Pritzkow M, Sarbia M, Bares R (2002) Early changes in [18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging 29: 1462-1469
18. Eastman A (1990) Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 2: 275-280
19. Engles JM, Quarless SA, Mambo E, Ishimori T, Cho SY, Wahl RL (2006) Stunning and its effect on 3H-FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy. J Nucl Med 47: 603-608
20. Fujibayashi Y, Waki A, Sakahara H, Konishi J, Yonekura Y, Ishii Y, Yokoyama A (1997) Transient increase in glycolytic metabolism in cultured tumor cells immediately after exposure to ionizing radiation: from gene expression to deoxyglucose uptake. Radiat Res 147: 729-734
21. Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP (1978) Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med 19: 1154-1161
22. Gilbert FJ, Park K, Thompson AM (2002) Scottish Audit of Gastric and Oesophageal Cancer: Report 1997-2000 - A prospective audit. http://www.show. scot.nhs.uk/crag/
23. Gonzalez VM, Fuertes MA, Alonso C, Perez JM (2001) Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 59: 657-663
24. Haberkorn U, Oberdorfer F, Klenner T, Strauss LG, Stohr M, Wallich R, Altmann A, Kaick GV (1994) Metabolic and transcriptional changes in osteosarcoma cells treated with chemotherapeutic drugs. Nucl Med Biol 21: 835-845
25. Higashi K, Clavo AC, Wahl RL (1993) Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 34: 414-419
26. Higashi T, Tamaki N, Honda T, Torizuka T, Kimura T, Inokuma T, Ohshio G, Hosotani R, Imamura M, Konishi J (1997) Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med 38: 1337-1344
27. Inada T, Ichikawa A, Igarashi S, Kubota T, Ogata Y (1997) Effect of preoperative 5-fluorouracil on apoptosis of advanced gastric cancer. J Surg Oncol 65: 106-110
28. Jordan P, Carmo-Fonseca M (2000) Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 57: 1229-1235
29. Kostakoglu L, Goldsmith SJ (2004) PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med 45: 56-68
30. Kroep JR, Van Groeningen CJ, Cuesta MA, Craanen ME, Hoekstra OS, Comans EF, Bloemena E, Hoekstra CJ, Golding RP, Twisk JW, Peters GJ, Pinedo HM, Lammertsma AA (2003) Positron emission tomography using 2-deoxy-2-[18F]-fluoro- D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods. Mol Imaging Biol 5: 337-346
31. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T (1992) Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 33: 1972-1980
32. Kurokawa T, Yoshida Y, Kawahara K, Tsuchida T, Okazawa H, Fujibayashi Y, Yonekura Y, Kotsuji F (2004) Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]- fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer 109: 926-932
33. Maruyama I, Sadato N, Waki A, Tsuchida T, Yoshida M, Fujibayashi Y, Ishii Y, Kubota T, Yonekura Y (1999) Hyperacute changes in glucose metabolism of brain tumors after stereotactic radiosurgery: a PET study. J Nucl Med 40: 1085-1090
34. Mathupala SP, Rempel A, Pedersen PL (1997) Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr 29: 339-343
35. Miccoli L, Oudard S, Sureau F, Poirson F, Dutrillaux B, Poupon MF (1996) Intracellular pH governs the subcellular distribution of hexokinase in a glioma cell line. Biochem J 313(Part 3): 957-962
36. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63
37. Mueckler M (1994) Facilitative glucose transporters. Eur J Biochem 219: 713-725
38. Nelson CA, Wang JQ, Leav I, Crane PD (1996) The interaction among glucose transport, hexokinase, and glucose-6-phosphatase with respect to 3H-2-deoxyglucose retention in murine tumor models. Nucl Med Biol 23: 533-541
39. Ott K, Fink U, Becker K, Stahl A, Dittler HJ, Busch R, Stein H, Lordick F, Link T, Schwaiger M, Siewert JR, Weber WA (2003) Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 21: 4604-4610
40. Park JK, Lee SH, Kang JH, Nishio K, Saijo N, Kuh HJ (2004) Synergistic interaction between gefitinib (Iressa, ZD1839) and paclitaxel against human gastric carcinoma cells. Anticancer Drugs 15: 809-818
41. Pinedo HM, Peters GF (1988) Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6: 1653-1664
42. Sekiguchi I, Suzuki M, Tamada T, Shinomiya N, Tsuru S, Murata M (1996) Effects of cisplatin on cell cycle kinetics, morphological change, and cleavage pattern of DNA in two human ovarian carcinoma cell lines. Oncology 53: 19-26
43. Shapiro GI, Edwards CD, Ewen ME, Rollins BJ (1998) p16INK4A participates in a G1 arrest checkpoint in response to DNA damage. Mol Cell Biol 18: 378-387
44. Smith TA (1999) Facilitative glucose transporter expression in human cancer tissue. Br J Biomed Sci 56: 285-292
45. Smith TA (2000) Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci 57: 170-178
46. Smith TA, Maisey NR, Titley JC, Jackson LE, Leach MO, Ronen SM (2000) Treatment of SW620 cells with Tomudex and oxaliplatin induces changes in 2-deoxy-D-glucose incorporation associated with modifications in glucose transport. J Nucl Med 41: 1753-1759
47. Smith TA, Sharma RI, Thompson AM, Paulin FE (2006) Tumor 18F-FDG incorporation is enhanced by attenuation of P53 function in breast cancer cells in vitro. J Nucl Med 47: 1525-1530
48. Sorenson CM, Barry MA, Eastman A (1990) Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 82: 749-755
49. Tohma T, Okazumi S, Makino H, Cho A, Mochiduki R, Shuto K, Kudo H, Matsubara K, Gunji H, Ochiai T (2005) Relationship between glucose transporter, hexokinase and FDG-PET in esophageal cancer. Hepatogastroenterology 52: 486-490
50. Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y, Tanaka A, Yamaoka Y, Yamamoto K, Konishi J (1995) In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 36: 1811-1817
51. Waki A, Kato H, Yano R, Sadato N, Yokoyama A, Ishii Y, Yonekura Y, Fujibayashi Y (1998) The importance of glucose transport activity as the rate-limiting step of 2-deoxyglucose uptake in tumor cells in vitro. Nucl Med Biol 25: 593-597
52. Wang G, Reed E, Li QQ (2004) Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review). Oncol Rep 12: 955-965
53. Warburg O (1956) On the origin of cancer cells. Science 123: 306-314
54. Weber G, Cantero A (1955) Glucose-6-phosphatase activity in normal, pre-cancerous, and neoplastic tissues. Cancer Res 15: 105-108
55. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, Meisetschlager G, Busch R, Siewert JR, Schwaiger M, Fink U (2001) Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19: 3058-3065
56. Yamane N, Makino M, Kaibara N (1999) S-phase accumulation precedes apoptosis induced by preoperative treatment with 5-fluorouracil in human colorectal carcinoma cells. Cancer 85: 309-317
57. Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J (1996) Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res 56: 1164-1167
58. Zhao S, Kuge Y, Mochizuki T, Takahashi T, Nakada K, Sato M, Takei T, Tamaki N (2005) Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. J Nucl Med 46: 675-682
59. Zhao S, Kuge Y, Tsukamoto E, Mochizuki T, Kato T, Hikosaka K, Nakada K, Hosokawa M, Kohanawa M, Tamaki N (2002) Fluorodeoxyglucose uptake and glucose transporter expression in experimental inflammatory lesions and malignant tumours: effects of insulin and glucose loading. Nucl Med Commun 23: 545-550
60. Zhou R, Vander Heiden MG, Rudin CM (2002) Genotoxic exposure is associated with alterations in glucose uptake and metabolism. Cancer Res 62: 3515-3520
61. Zoli W, Ricotti L, Tesei A, Ulivi P, Gasperi Campani A, Fabbri F, Gunelli R, Frassineti GL, Amadori D (2004) Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro. Clin Cancer Res 10: 1500-1507